1 Department of Medicine, Jaleshwor Hospital, Janakpur, Nepal.
2 Department of Medicine, Annapurna Neuro Hospital, Kathmandu, Nepal.
3 Department of Medicine, Butwal Hospital, Butwal, Nepal.
4 Department of Medicine, Nepal APF Hospital, Kathmandu, Nepal.
5 Department of Medicine, College of Medical Sciences (CMS), Bharatpur, Nepal.
6 Department of Medicine, Bharatpur Hospital, Bharatpur, Nepal.
7 Scientific Services, USV Pvt Ltd, Mumbai, India.
World Journal of Advanced Research and Reviews, 2025, 25(02), 1984-1992
Article DOI: 10.30574/wjarr.2025.25.2.0445
Received on 31 December 2024; revised on 11 February 2025; accepted on 14 February 2025
Background: The fixed drug combination (FDC) of glimepiride and metformin effectively controls blood glucose and improves glycated hemoglobin (HbA1c). This study aimed to evaluate the effectiveness and safety of the FDC of glimepiride and metformin in managing type-2 diabetes mellitus (T2DM).
Materials and Methods: This retrospective, non-comparative, multi-center cross-sectional study was conducted at tertiary care centers in Nepal. Adult patients (aged 18 years or older) with T2DM were included. Primary outcomes included changes in HbA1c, fasting plasma glucose (FPG), and postprandial glucose (PPG) levels.
Results: A total of 287 patients were included in the study, with a mean age of 55.6 years and a predominance of females (62.41%). The average body mass index was 27.49 kg/m² and the median duration of T2DM was 4 years. Common risk factors included obesity (53.31%), smoking (45.30%), and a sedentary lifestyle (36.59%). The most prevalent treatment regimen was the combination of glimepiride 1 mg and metformin 1000 mg sustained release (54.77%). Post-glimepiride and metformin 1000 mg sustained release, the mean changes in HbA1c, FPG, and PPG were significant, with reductions of 2.45%, 64.53 mg/dL, and 102.64 mg/dL, respectively (P<0.001, each). Overall, physicians evaluated the efficacy and tolerability as good to excellent responses in a higher proportion of patients (94.9% and 96.2%, respectively).
Conclusion: The combination of glimepiride and metformin 1000 mg sustained release effectively improves glycemic control in patients with T2DM while demonstrating a favorable safety profile
Fasting plasma glucose; Glycated hemoglobin; Glycemic control; Obesity
Preview Article PDF
Ram Pratap Sah, Pratik Paudel, Saroj Thapa, Mahendra Raj Shrestha, Manoj Shrestha, Sunil Poudyal, Aushili Mahule. Assessing the efficacy and safety of combined glimepiride and metformin therapy in type 2 diabetes mellitus management. World Journal of Advanced Research and Reviews, 2025, 25(02), 1984-1992. Article DOI: https://doi.org/10.30574/wjarr.2025.25.2.0445.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0